Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 161

1.

Within the Brain: The Renin Angiotensin System.

Jackson L, Eldahshan W, Fagan SC, Ergul A.

Int J Mol Sci. 2018 Mar 15;19(3). pii: E876. doi: 10.3390/ijms19030876. Review.

2.

Dose-response, therapeutic time-window and tPA-combinatorial efficacy of compound 21: A randomized, blinded preclinical trial in a rat model of thromboembolic stroke.

Ishrat T, Fouda AY, Pillai B, Eldahshan W, Ahmed H, Waller JL, Ergul A, Fagan SC.

J Cereb Blood Flow Metab. 2018 Jan 1:271678X18764773. doi: 10.1177/0271678X18764773. [Epub ahead of print]

PMID:
29537907
3.

Role of angiotensin system modulation on progression of cognitive impairment and brain MRI changes in aged hypertensive animals - A randomized double- blind pre-clinical study.

Ahmed HA, Ishrat T, Pillai B, Bunting KM, Patel A, Vazdarjanova A, Waller JL, Arbab AS, Ergul A, Fagan SC.

Behav Brain Res. 2018 Jul 2;346:29-40. doi: 10.1016/j.bbr.2017.12.007. Epub 2017 Dec 8.

PMID:
29229547
4.

Peroxynitrite-Induced Tyrosine Nitration Contributes to Matrix Metalloprotease-3 Activation: Relevance to Hyperglycemic Ischemic Brain Injury and Tissue Plasminogen Activator.

Hafez S, Abdelsaid M, Fagan SC, Ergul A.

Neurochem Res. 2018 Feb;43(2):259-266. doi: 10.1007/s11064-017-2411-9. Epub 2017 Oct 3.

PMID:
28975464
5.

Minocycline in Acute Cerebral Hemorrhage: An Early Phase Randomized Trial.

Fouda AY, Newsome AS, Spellicy S, Waller JL, Zhi W, Hess DC, Ergul A, Edwards DJ, Fagan SC, Switzer JA.

Stroke. 2017 Oct;48(10):2885-2887. doi: 10.1161/STROKEAHA.117.018658. Epub 2017 Sep 8.

PMID:
28887388
6.

Mechanisms of acute neurovascular protection with AT1 blockade after stroke: Effect of prestroke hypertension.

Alhusban A, Kozak A, Pillai B, Ahmed H, Sayed MA, Johnson MH, Ishrat T, Ergul A, Fagan SC.

PLoS One. 2017 Jun 22;12(6):e0178867. doi: 10.1371/journal.pone.0178867. eCollection 2017.

7.

Diabetes Worsens Functional Outcomes in Young Female Rats: Comparison of Stroke Models, Tissue Plasminogen Activator Effects, and Sexes.

Li W, Ward R, Valenzuela JP, Dong G, Fagan SC, Ergul A.

Transl Stroke Res. 2017 Mar 1. doi: 10.1007/s12975-017-0525-7. [Epub ahead of print]

PMID:
28247188
8.

Role of interleukin-10 in the neuroprotective effect of the Angiotensin Type 2 Receptor agonist, compound 21, after ischemia/reperfusion injury.

Fouda AY, Pillai B, Dhandapani KM, Ergul A, Fagan SC.

Eur J Pharmacol. 2017 Mar 15;799:128-134. doi: 10.1016/j.ejphar.2017.02.016. Epub 2017 Feb 10.

9.

Nox4 contributes to the hypoxia-mediated regulation of actin cytoskeleton in cerebrovascular smooth muscle.

Coucha M, Abdelsaid M, Li W, Johnson MH, Orfi L, El-Remessy AB, Fagan SC, Ergul A.

Life Sci. 2016 Oct 15;163:46-54. doi: 10.1016/j.lfs.2016.08.018. Epub 2016 Aug 21.

10.

ARBs improve stroke outcome through an AT2-dependent, BDNF-induced proangiogenic and prorecovery response.

Alhusban A, Fouda AY, Fagan SC.

Neural Regen Res. 2016 Jun;11(6):912-3. doi: 10.4103/1673-5374.184484. No abstract available.

11.

Erratum to: Artery reopening is required for the neurorestorative effects of angiotensin modulation after experimental stroke.

Alhusban A, Kozak A, Eldahshan W, Ergul A, Fagan SC.

Exp Transl Stroke Med. 2016 Jun 14;8:5. doi: 10.1186/s13231-016-0019-9. eCollection 2016.

12.

Artery reopening is required for the neurorestorative effects of angiotensin modulation after experimental stroke.

Alhusban A, Kozak A, Eldashan W, Ergul A, Fagan SC.

Exp Transl Stroke Med. 2016 Apr 27;8:4. doi: 10.1186/s13231-016-0018-x. eCollection 2016. Erratum in: Exp Transl Stroke Med. 2016;8:5.

13.

Impact of Comorbidities on Acute Injury and Recovery in Preclinical Stroke Research: Focus on Hypertension and Diabetes.

Ergul A, Hafez S, Fouda A, Fagan SC.

Transl Stroke Res. 2016 Aug;7(4):248-60. doi: 10.1007/s12975-016-0464-8. Epub 2016 Mar 30. Review.

14.

Matrix Metalloprotease 3 Exacerbates Hemorrhagic Transformation and Worsens Functional Outcomes in Hyperglycemic Stroke.

Hafez S, Abdelsaid M, El-Shafey S, Johnson MH, Fagan SC, Ergul A.

Stroke. 2016 Mar;47(3):843-51. doi: 10.1161/STROKEAHA.115.011258. Epub 2016 Feb 2.

15.

Renin-angiotensin system as a potential therapeutic target in stroke and retinopathy: experimental and clinical evidence.

Fouda AY, Artham S, El-Remessy AB, Fagan SC.

Clin Sci (Lond). 2016 Feb;130(4):221-38. doi: 10.1042/CS20150350. Review.

PMID:
26769658
16.

Brain-Derived Neurotrophic Factor Knockdown Blocks the Angiogenic and Protective Effects of Angiotensin Modulation After Experimental Stroke.

Fouda AY, Alhusban A, Ishrat T, Pillai B, Eldahshan W, Waller JL, Ergul A, Fagan SC.

Mol Neurobiol. 2017 Jan;54(1):661-670. doi: 10.1007/s12035-015-9675-3. Epub 2016 Jan 12.

17.

Vascular protective effects of Angiotensin Receptor Blockers: Beyond Blood pressure.

Artham S, Fouda AY, El-Remessy AB, Fagan SC.

Receptors Clin Investig. 2015;2(3). pii: e774. No abstract available.

18.

The Akt inhibitor, triciribine, ameliorates chronic hypoxia-induced vascular pruning and TGFβ-induced pulmonary fibrosis.

Abdalla M, Sabbineni H, Prakash R, Ergul A, Fagan SC, Somanath PR.

Br J Pharmacol. 2015 Aug;172(16):4173-88. doi: 10.1111/bph.13203. Epub 2015 Jul 6.

19.

Sequential Therapy with Minocycline and Candesartan Improves Long-Term Recovery After Experimental Stroke.

Soliman S, Ishrat T, Fouda AY, Patel A, Pillai B, Fagan SC.

Transl Stroke Res. 2015 Aug;6(4):309-22. doi: 10.1007/s12975-015-0408-8. Epub 2015 May 26.

20.

Vascular protection with dipeptidyl peptidase-IV inhibitors in diabetes: experimental and clinical therapeutics.

Ahmed HA, May DW, Fagan SC, Segar L.

Pharmacotherapy. 2015 Mar;35(3):277-97. doi: 10.1002/phar.1547. Epub 2015 Mar 10. Review.

PMID:
25754657

Supplemental Content

Loading ...
Support Center